Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

836 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.
Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM, Bargallo X, García-Criado A, de Lazzari E, Larrousse M, León A, Loncá M, Milinkovic A, Gatell JM, Mallolas J. Laguno M, et al. Among authors: gatell jm. AIDS. 2004 Sep 3;18(13):F27-36. doi: 10.1097/00002030-200409030-00003. AIDS. 2004. PMID: 15316335 Clinical Trial.
Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosine.
Miró O, López S, Rodríguez de la Concepción M, Martínez E, Pedrol E, Garrabou G, Giralt M, Cardellach F, Gatell JM, Vilarroya F, Casademont J. Miró O, et al. Among authors: gatell jm. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1550-5. doi: 10.1097/00126334-200412150-00002. J Acquir Immune Defic Syndr. 2004. PMID: 15577406 Clinical Trial.
Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study).
Ribera E, Azuaje C, Lopez RM, Domingo P, Soriano A, Pou L, Sánchez P, Mallolas J, Sambea MA, Falco V, Ocaña I, Lopez-Colomes JL, Gatell JM, Pahissa A. Ribera E, et al. Among authors: gatell jm. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):317-23. doi: 10.1097/01.qai.0000182629.74336.4d. J Acquir Immune Defic Syndr. 2005. PMID: 16249706 Clinical Trial.
Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).
Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J; PISCIS Study Group. Jaén A, et al. Among authors: gatell jm. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):212-20. doi: 10.1097/qai.0b013e31815ee282. J Acquir Immune Defic Syndr. 2008. PMID: 18297762
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.
Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, von Wyl V, Lazzarin A, Katlama C, Phillips AN, Ruiz L, Lundgren JD; EuroSIDA study group. Bannister WP, et al. J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):324-33. doi: 10.1097/QAI.0b013e31817ae5c0. J Acquir Immune Defic Syndr. 2008. PMID: 18545152 Clinical Trial.
Effect of TNF-alpha genetic variants and CCR5 Delta 32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards.
Veloso S, Olona M, García F, Domingo P, Alonso-Villaverde C, Broch M, Peraire J, Viladés C, Plana M, Pedrol E, López-Dupla M, Aguilar C, Gutiérrez M, Leon A, Tasias M, Gatell JM, Richart C, Vidal F. Veloso S, et al. Among authors: gatell jm. BMC Med Genet. 2010 Apr 26;11:63. doi: 10.1186/1471-2350-11-63. BMC Med Genet. 2010. PMID: 20420684 Free PMC article.
836 results